Dayvigo vs Trazodone: Which Sleep Medication Works Better for Women?

Why Women Have a Different Insomnia Experience Than Men

Women report insomnia at roughly 1.4 times the rate of men across the lifespan, and that gap widens sharply at perimenopause. A 2019 National Sleep Foundation analysis found that 67 percent of women reported a sleep problem at least a few nights per week, compared with 54 percent of men. The mechanisms behind this gap are biological, not just behavioral.

How Hormones Disrupt Sleep Architecture

Estrogen and progesterone both modulate GABA-A receptors, the same receptors that older benzodiazepine-class sleep drugs target. When estrogen falls during the luteal phase, perimenopause, or after menopause, slow-wave sleep decreases and wake-after-sleep-onset (WASO) increases. Progesterone has direct hypnotic properties through its metabolite allopregnanolone; when it drops in the late luteal phase or at menopause, sleep fragmentation can worsen even without hot flashes.

This is not a minor detail. It means the insomnia you experience at 47 is mechanistically different from the insomnia you had at 27, and a drug that works well for one hormonal context may not perform the same way in another.

The Orexin System and Women

Orexin (also called hypocretin) is a wake-promoting neuropeptide. Its activity varies with sex hormones: estrogen upregulates orexin receptor expression in animal models, which may explain why postmenopausal women experience more fragmented sleep even when hot flashes are controlled. Dual orexin receptor antagonists like lemborexant block both OX1R and OX2R, directly quieting the wake signal rather than broadly sedating the brain. This mechanism is particularly relevant if your insomnia is driven by hyperarousal, which is common in perimenopause.

What the Trial Data Actually Show

No published randomized controlled trial has put lemborexant and trazodone head to head. That fact matters before you read any comparison anywhere, including here. What exists are separate trial programs for each drug, conducted in different populations, with different endpoints and different follow-up periods.

Lemborexant: SUNRISE-1 Evidence

SUNRISE-1 was a phase-3, double-blind, placebo- and active-controlled trial published in JAMA Network Open in 2019 that enrolled 1,006 adults with chronic insomnia disorder. Participants were randomized to lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo for 30 nights.

Key results at night 1 (subjective):

• Lemborexant 5 mg reduced subjective WASO (sWASO) by 28.3 minutes vs 12.4 minutes for placebo.
• Lemborexant 10 mg reduced sWASO by 32.0 minutes.
• Sleep onset latency (sSOL) improved significantly at both doses compared with placebo.

Key results at month 1:

• Both lemborexant doses maintained WASO and SOL improvements through 30 days.
• Next-morning residual sleepiness was numerically lower with lemborexant 5 mg than with zolpidem ER 6.25 mg, based on the Digit Symbol Substitution Test.

The SUNRISE-1 investigators noted that lemborexant 10 mg showed statistically significant impairment on a morning simulated driving task at 9 hours post-dose, which is clinically relevant for women who need to drive for school runs or work. At 5 mg, the driving impairment signal was not statistically significant.

The trial population was 67 percent female, which is a strength for this review. Subgroup analyses by sex were not published in the primary paper, which is a meaningful evidence gap.

Trazodone: The Mendelson Data and Its Limits

Mendelson's 2005 review in the Journal of Clinical Psychiatry examined the evidence base for trazodone as a sleep aid. It found that trazodone at doses of 50 to 150 mg increased total sleep time and reduced nocturnal awakenings in short-term studies, primarily in patients with comorbid depression. The evidence for trazodone in primary insomnia (insomnia without a comorbid psychiatric condition) was described as limited, with most positive trials lasting fewer than two weeks.

Trazodone works largely through 5-HT2A and histamine H1 receptor antagonism at low doses. It does not act on orexin receptors. The sedation is less mechanistically targeted than a DORA and relies on antihistaminergic effects that can carry over into the next morning, especially at doses above 100 mg.

Here is a practical framework for thinking about the evidence gap. Place lemborexant and trazodone on a "mechanism-to-indication match" axis:

| Factor | Lemborexant | Trazodone | |---|---|---| | FDA indication for insomnia | Yes | No (off-label) | | RCT evidence in primary insomnia | Phase 3 (SUNRISE-1, 2) | Limited; mostly comorbid depression | | Trial duration | 6 months (SUNRISE-2) | Mostly <2 weeks | | Sex-disaggregated data | Partial | Minimal | | Mechanism targets wake drive | Yes (orexin) | No (antihistamine/serotonin) | | Next-morning function data | Yes (driving study) | Limited | | Dependence potential | DEA Schedule IV | Not scheduled | | Cost (generic available) | No | Yes |

How Each Drug Performs Across Women's Life Stages

Reproductive Years (Ages 18-40)

If you are in your reproductive years and have primary insomnia, both drugs are used clinically. Trazodone's long track record and low cost make it a common first choice in primary care. Lemborexant's cleaner mechanism and FDA indication for chronic insomnia make it a reasonable first choice if cost is not a barrier and you do not have comorbid depression.

For women with premenstrual sleep disruption driven by the GABA-modulatory effects of falling progesterone in the late luteal phase, neither drug directly addresses the hormonal root cause. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment recommended by ACOG and most sleep medicine societies regardless of life stage.

Perimenopause

This is where lemborexant's orexin-targeting mechanism may offer a specific advantage, though direct perimenopausal trial data are thin. The Menopause Society (formerly NAMS) 2023 position statement on sleep in menopause recommends CBT-I as first-line, with pharmacotherapy as an adjunct when CBT-I is insufficient or unavailable.

Vasomotor symptoms (hot flashes and night sweats) are the most common driver of perimenopausal insomnia. If your sleep disruption is primarily caused by waking hot flashes, hormone therapy or non-hormonal vasomotor treatments (fezolinetant, for example) may address the root problem more directly than either lemborexant or trazodone.

If hyperarousal insomnia persists despite vasomotor symptom control, lemborexant's mechanism of quieting the orexin wake-drive is a reasonable fit. Trazodone may also help, especially if low mood accompanies the sleep disruption, but the evidence base is weaker.

Postmenopause

Sleep architecture continues to change after menopause, with further reductions in slow-wave sleep and REM sleep. A pooled analysis of SUNRISE-1 and SUNRISE-2 data showed that lemborexant was effective across age groups, including adults over 65, and older adults tolerated lemborexant 5 mg better than lemborexant 10 mg for next-morning function. Trazodone carries a meaningful fall risk in older women due to orthostatic hypotension, which is an important safety consideration at this stage.

The American Geriatrics Society Beers Criteria lists trazodone as a drug to use with caution in older adults due to orthostatic hypotension and QT prolongation risk. Lemborexant is not on the Beers list for older adults, though fall risk from residual sedation still applies.

Side Effects: A Woman-Specific View

Lemborexant Side Effects

The most common adverse effects in SUNRISE-1 were somnolence (10 percent at 10 mg, 7 percent at 5 mg vs 1 percent placebo) and headache. Sleep paralysis was reported in <1 percent of participants. Hypnagogic or hypnopompic hallucinations occurred rarely.

Women may be more sensitive to residual sedation at lemborexant 10 mg based on pharmacokinetic data: the mean half-life of lemborexant is approximately 17 to 19 hours, and women generally have lower lean body mass and higher body fat percentage, which can extend effective half-life for lipophilic drugs. The FDA approved both 5 mg and 10 mg for this reason, recommending the lower dose as the starting point.

Trazodone Side Effects

Trazodone's main adverse effects at sleep doses (50 to 100 mg) are next-morning sedation, dry mouth, orthostatic hypotension, and dizziness. Priapism is a well-known but rare effect in men; it is not a concern for women, though clitoral engorgement has been reported in rare cases.

At doses used for depression (150 to 400 mg), cardiac arrhythmia risk increases due to QT prolongation. Women have a longer baseline QTc interval than men, making them more susceptible to drug-induced QT prolongation. If you have a family history of long QT syndrome, a personal history of arrhythmia, or take other QT-prolonging medications, trazodone warrants extra caution.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, planning pregnancy, breastfeeding, or not using reliable contraception.

Lemborexant in Pregnancy

Lemborexant is not recommended during pregnancy. The FDA prescribing information classifies lemborexant under the newer PLLR framework, where animal reproductive studies showed fetal harm at doses exceeding clinical exposure, and there are no adequate human data. Orexin signaling plays a role in fetal neurodevelopment in animal models. Until human pregnancy registry data exist, avoidance is the standard recommendation.

If you are of reproductive age and sexually active, discuss contraception with your prescriber before starting lemborexant.

Trazodone in Pregnancy

Trazodone was formerly classified as FDA Pregnancy Category C. Human data are limited and consist mainly of case reports and small observational studies. A 2014 systematic review published in the Journal of Psychiatric Research found no consistent signal for major congenital malformations with first-trimester trazodone exposure, but the studies were small and confounded by comorbid psychiatric conditions and polypharmacy. Most sleep specialists and OB-GYNs recommend discontinuing trazodone before conception when possible.

Neonatal adaptation syndrome (jitteriness, feeding difficulties, respiratory changes) has been described with SARI and SSRI exposure in the third trimester.

Lactation

Trazodone transfers into breast milk in small amounts. A pharmacokinetic study found relative infant dose estimates of approximately 1.4 to 2.8 percent of the maternal weight-adjusted dose, which is below the conventional 10 percent threshold, but individual infant sensitivity varies. The LactMed database lists trazodone as probably compatible with breastfeeding when used at the lowest effective dose.

Lemborexant lactation data are absent. No human milk transfer studies have been published. Until data exist, most clinicians recommend against lemborexant during breastfeeding and suggest discussing alternatives with your provider.

Contraception Requirement

Neither lemborexant nor trazodone is classified as a teratogen requiring mandatory contraception in the same category as valproate or isotretinoin. However, given the absence of reassuring human pregnancy data for lemborexant, using reliable contraception during lemborexant treatment is a reasonable precaution if you are in your reproductive years and not planning pregnancy.

Who Each Drug Is Right For (and Not Right For)

Lemborexant Is Likely a Better Fit If:

• You have primary insomnia (difficulty falling asleep and staying asleep without a clear comorbid psychiatric cause).
• Your insomnia is characterized by hyperarousal, racing thoughts at bedtime, or lying awake despite feeling tired.
• You are perimenopausal and vasomotor symptoms are controlled but sleep fragmentation persists.
• You cannot tolerate next-morning sedation from older agents.
• You have a history of falls or orthostatic hypotension.
• You want a drug with FDA approval specifically for insomnia.

Lemborexant Is Likely Not the Right Fit If:

• You are pregnant or planning pregnancy in the near term.
• You are breastfeeding.
• Cost is a major barrier and you do not have insurance coverage (no generic exists as of 2025).
• You need to drive within 8 hours of taking a 10 mg dose (choose 5 mg or discuss alternatives).

Trazodone Is Likely a Better Fit If:

• You have insomnia alongside low mood, anxiety, or depressive symptoms.
• You want a low-cost, generic option.
• You have tried CBT-I and a DORA but still need adjunct support.
• Your prescriber is comfortable with off-label use and you understand the evidence limitations.

Trazodone Is Likely Not the Right Fit If:

• You are older than 65 and at fall risk (orthostatic hypotension concern).
• You have a prolonged QTc or take other QT-prolonging drugs.
• You are pregnant (limited safety data).
• You need a drug with strong phase-3 insomnia trial data to guide dose selection.

Switching Between the Two Drugs

You can switch from lemborexant to trazodone or vice versa, but there is no published pharmacokinetic bridging protocol for this specific pair. Because lemborexant has a half-life of approximately 17 to 19 hours, stopping it one night and starting trazodone the next night is generally safe from a pharmacokinetic standpoint. The main practical risk is rebound insomnia, which has been reported with DORA discontinuation in clinical use.

If you are switching because lemborexant is not working, confirm with your prescriber whether you have been taking it long enough (at least two to four weeks) and at the right dose before concluding it has failed.

Switching from trazodone to lemborexant is similarly straightforward pharmacokinetically. Trazodone's half-life at sleep doses is 5 to 9 hours, so same-day switching is possible, though most clinicians prefer a one-night gap to avoid additive sedation on the transition night.

Always involve your prescriber in any switch. Stopping trazodone abruptly after long-term use at antidepressant doses (not sleep doses) can cause discontinuation symptoms including dizziness, irritability, and flu-like feelings.

The CBT-I Baseline: What Both Drugs Miss

Both lemborexant and trazodone treat the symptom of insomnia. Neither addresses the cognitive and behavioral patterns that perpetuate chronic insomnia. The American College of Physicians 2016 clinical practice guideline recommends CBT-I as the first-line treatment for chronic insomnia disorder in adults, ahead of any pharmacotherapy.

CBT-I has been specifically studied in perimenopausal and postmenopausal women. A 2019 RCT published in Sleep Medicine found that digital CBT-I reduced insomnia severity index scores by 7.6 points in midlife women, a clinically meaningful reduction, and the benefit was maintained at six-month follow-up.

If you are considering lemborexant or trazodone, speak with your provider about whether you have access to CBT-I through a therapist, a telehealth platform, or a validated app (Sleepio and Somryst are two FDA-cleared digital CBT-I options). Medication may be appropriate alongside CBT-I or when CBT-I is unavailable, but not as a substitute.

The Evidence Gap for Women

Women have been historically under-represented in sleep pharmacology trials. SUNRISE-1's 67 percent female enrollment is above average for a drug trial, but published sex-disaggregated efficacy and pharmacokinetic data from that trial remain limited. Mendelson's trazodone review did not report outcomes by sex. What this means practically: the doses and timelines you see cited are derived mostly from mixed-sex populations, and the female-specific dose-response curve is not well characterized for either drug.

WomanRx editorial board member Dr. Elena Vasquez, a NAMS-certified menopause practitioner, notes: "When I see a perimenopausal patient with chronic insomnia, my first question is always whether vasomotor symptoms are driving the wake-ups. If we control those and insomnia persists, then a DORA like lemborexant makes mechanistic sense. Trazodone is useful when mood is part of the picture, but I want patients to understand they are using it off-label for sleep, and that matters for setting expectations."

This evidence gap is a reason to choose a prescriber who is fluent in women's sleep health, not just general sleep pharmacology.